Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,486 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK |
| 1 |
| Sep 4, 2020 |
| clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04193696 | RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | unknown | Phase 2 | 39 | Guangxi Medical UniversityOTHER | 0 | Jan 9, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04077983 | Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 4, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04014101 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma(SHR-1210) | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03728543 | the Efficacy and Safety of Sugammadex in Children 0-2 Years Old | unknown | Phase 2 / Phase 3 | 62 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01834963 | P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. | unknown | Phase 2 | 66 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | May 18, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | unknown | Phase 2 | 50 | Guangxi Medical UniversityOTHER | 0 | May 9, 2018 | clinicaltrials |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | unknown | Phase 2 | 40 | Guangxi Medical UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Oct 5, 2020source: clinicaltrials